Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
Arvinas, Inc. announced its participation in the Michael J. Fox Foundation-supported LRRK2 Investigative Therapeutics Exchange (LITE) and Parkinson’s Precision Medicine Initiative (PPMI) programs. This collaboration aims to advance ARV-102, an investigational PROTAC drug targeting LRRK2 for treating Parkinson’s disease and related neurodegenerative…